Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet function

被引:34
作者
Rotondo, S [1 ]
Dell'Elba, G [1 ]
Krauze-Brzósko, K [1 ]
Manarini, S [1 ]
Martelli, N [1 ]
Pecce, R [1 ]
Evangelista, V [1 ]
Cerletti, C [1 ]
机构
[1] Consorzio Mario Negri Sud, Ist Ric Farmacol Mario Negri, G Bizzozero Lab Blood & Vasc Cell Interact, I-66030 Santa Maria Imbaro, Italy
关键词
inflammation; polymorphonuclear leukocyte; human; 5-lipoxygenase; cyclooxygenase; transcellular metabolism; adhesive interaction;
D O I
10.1016/S0014-2999(02)02385-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Polymorphonuclear leukocytes are strongly implicated in the pathogenesis of inflammatory disease. Polymorphonuclear leukocyte recruitment at sites of inflammation, mainly sustained by the beta2-integrins, is followed by the synthesis and release of inflammatory mediators, such as leukotrienes, proteolytic enzymes and reactive oxygen species. Functional and metabolic interactions between polymorphonuclear leukocytes and platelets can contribute to and exacerbate the process. The effects of the dual 5-lipoxygenase and cyclooxygenase inhibitor licofelone ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid) were studied on arachidonic acid transcellular metabolism occurring between polymorphonuclear leukocytes and platelets. The formation of leukotriene C-4, a leukotriene A(4)-derived metabolite, by mixed polymorphonuclear leukocyte/platelet suspensions stimulated with 10 muM A23187 was inhibited by licofelone with an IC50 of 3.8 +/- 0.07 muM. The formation of 5,12-di-hydroxy-eicosatetraenoic acid (HETE) was abolished at concentrations greater than or equal to 10 muM. Licofelone also inhibited the generation of reactive oxygen species by polymorphonuclear leukocytes stimulated with 1 muM n-formyl-methionyl-leucyl-phenylalanine (MLP), 10 nM complement fraction 5a (C5a) and 1 muM platelet activating factor (PAF) with IC(50)s of 24.4 +/- 0.6, 11.0 +/- 1.5 and 11.7 +/- 1.2 muM; elastase release induced by the three agonists was inhibited with IC(50)s of 12.2 +/- 2.2, 23.5 +/- 8 and 2.6 +/- 1 muM, respectively. Homotypic polymorphonuclear leukocyte aggregation induced by fMLP, C5A and PAF was inhibited by licofelone with IC(50)s of 23.7 +/- 4.8, 15.6 +/- 3.4 and 15.4 +/- 4 muM, respectively. The present study extends the anti-lipoxygenase and anticyclooxygenase activities of licofelone to the production of arachidonic acid metabolites generated as a consequence of polymorphonuclear leukocyte-platelet transcellular metabolism and to polymorphonuclear leukocyte responses relevant to the pathogenesis of inflammation. The coexistence within the same molecule of a wide spectrum of anti-inflammatory properties is of interest. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:131 / 139
页数:9
相关论文
共 37 条
[1]   The effects of ML 3000 on antigen-induced responses in sheep [J].
Abraham, WM ;
Laufer, S ;
Tries, S .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 1997, 10 (03) :167-173
[2]  
ALGATE DR, 1995, ARZNEIMITTEL-FORSCH, V45-1, P159
[3]  
ARNAOUT MA, 1990, BLOOD, V75, P1037
[4]  
BAZZONI G, 1991, BLOOD, V77, P2042
[5]   ADHESION PROMOTES TRANSCELLULAR LEUKOTRIENE BIOSYNTHESIS DURING NEUTROPHIL-GLOMERULAR ENDOTHELIAL-CELL INTERACTIONS - INHIBITION BY ANTIBODIES AGAINST CD18 AND L-SELECTIN [J].
BRADY, HR ;
SERHAN, CN .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 186 (03) :1307-1314
[6]   SIMULTANEOUS DETERMINATION OF LEUKOTRIENES B(4) AND E(4) IN WHOLE-BLOOD AND OF LEUKOTRIENE E(4) IN URINE OF RABBIT BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
CELARDO, A ;
DELLELBA, G ;
ELTANTAWY, ZM ;
EVANGELISTA, V ;
CERLETTI, C .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 658 (02) :261-269
[7]  
Cerletti C, 1999, THROMB HAEMOSTASIS, V82, P787
[8]   STEREOSPECIFIC INHIBITION OF PGH2-INDUCED PLATELET-AGGREGATION BY LIPOXYGENASE PRODUCTS OF ICOSAENOIC ACIDS [J].
CROSET, M ;
LAGARDE, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1983, 112 (03) :878-883
[9]  
Cuzzocrea S, 2001, PHARMACOL REV, V53, P135
[10]  
DEIGNER HP, 1995, ARZNEIMITTEL-FORSCH, V45-1, P272